TENX trades 131.6% below Wall Street's consensus target of $4.40.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TENX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Tenax Therapeutics, Inc. (TENX) has a Wall Street consensus price target of $4.40, based on estimates from 9 covering analysts. With the stock currently trading at $1.90, this represents a potential upside of +131.6%. The company has a market capitalization of $97M.
Analyst price targets range from a low of $4.00 to a high of $5.00, representing a 23% spread in expectations. The median target of $4.00 differs from the mean, suggesting potential outlier estimates. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, TENX trades at a trailing P/E of -1.4x. Analysts expect EPS to grow -14.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ATHAAthira Pharma, Inc. | $17M | $4.34 | — | — | — | — | — |
 NKTRNektar Therapeutics | $1.9B | $57.66 | $152.50 | +164.5% | Buy | — | 33 |
 ACADACADIA Pharmaceuticals Inc. | $4.4B | $25.43 | $33.83 | +33.0% | Buy | 41.1x | 37 |
 PRTAProthena Corporation plc | $454M | $8.68 | $30.00 | +245.6% | Buy | 78.9x | 28 |
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
 MDGLMadrigal Pharmaceuticals, Inc. | $11.8B | $513.02 | $677.00 | +32.0% | Buy | — | 25 |
 ESPREsperion Therapeutics, Inc. | $661M | $3.18 | $3.19 | +0.3% | Hold | — | 25 |
 RCKTRocket Pharmaceuticals, Inc. | $330M | $3.02 | $9.00 | +198.0% | Buy | — | 19 |
 ARDXArdelyx, Inc. | $860M | $3.48 | $13.00 | +273.6% | Buy | — | 16 |
 XNCRXencor, Inc. | $1.8B | $24.26 | $34.40 | +41.8% | Buy | — | 28 |
Quick answers to the most common questions about buying TENX stock.
The consensus Wall Street price target for TENX is $4.4, representing 131.6% upside from the current price of $1.9. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TENX has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $4.4 implies 131.6% upside from current levels.
TENX's current price is $1.9 with a consensus target of $4.4 (131.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for TENX, while the most conservative target is $4. The consensus of $4.4 represents the median expectation. These targets typically reflect 12-month expectations.
TENX is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TENX stock forecast based on 9 Wall Street analysts shows a consensus price target of $4.4, with estimates ranging from $4 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TENX, with a "Buy" consensus rating and $4.4 price target (131.6% upside). 6 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TENX analyst price targets range from $4 to $5, a 23% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.4 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.